Clinical Trials Directory

Trials / Unknown

UnknownNCT04550806

Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Prediction

The Predictive Ability of Glycated Albumin Combined With Body Composition for Gestational Diabetes Mellitus Diagnosis

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Peking Union Medical College Hospital · Academic / Other
Sex
Female
Age
22 Years – 45 Years
Healthy volunteers
Accepted

Summary

This study is going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis.

Detailed description

The prevalence of GDM is increasing all over the world. It has bad influence for both pregnant women and fetus. Early treatment is useful for GDM prevention. Therefore early screening is important for healthcare doctors to detect the potential patients. Glycated albumin (GA) is an optimal index for blood glucose evaluation compared to HbA1c, however it may be influenced by body weight and composition. The investigators are going to investigate the predictive ability of glycated albumin combined with body composition, including body weight, BMI, fat free mass and fat mass for gestational diabetes mellitus (GDM) diagnosis. This study recruit pregnant women before 12 weeks of their pregnant age and test GA level and body composition via bioelectrical impedance analysis. During 24-28 weeks of pregnant age, all participants will do the glucose tolerant test for GDM diagnosis.

Conditions

Timeline

Start date
2020-10-01
Primary completion
2021-06-01
Completion
2021-07-01
First posted
2020-09-16
Last updated
2020-10-20

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04550806. Inclusion in this directory is not an endorsement.